Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel
Article
Ortmann, O., Pagani, O., Jones, A., Maass, N., Noss, D., Rugo, H., van de Velde, C., Aapro, Matti and Coleman, R. (2011) Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treatment Reviews 37 (2), pp. 97-104.Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Cancer Treatment Reviews | ||||
| Publisher | ELSEVIER SCI LTD | ||||
| Place of Publication | OXFORD | ||||
| Volume | 37 | ||||
| Number of Issue or Book Chapter | 2 | ||||
| Page Range | pp. 97-104 | ||||
| Date | 2011 | ||||
| Date of publication | 19 Dec 2024 11:13 | ||||
| Institutions | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) | ||||
| Identification Number |
| ||||
| Keywords | CHEMOTHERAPY-INDUCED AMENORRHEA; MENOPAUSAL TRANSITION; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; ADJUVANT THERAPY; BONE LOSS; TAMOXIFEN; LETROZOLE; HORMONE; YOUNGER; Adjuvant therapy; Aromatase inhibitors; Breast cancer; Menopause; Perimenopause; Tamoxifen | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 65099 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric